Sector News

Biogen poaches Pfizer dealmaker Dan Karp for stepped-up M&A push

May 31, 2018
Life sciences

Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing.

On Thursday, the big biotech said it had brought on Pfizer veteran Dan Karp as its EVP of corporate development, ending his stint as the pharma giant’s VP of worldwide business development and head of R&D business development. For Biogen, Karp will lead a newly minted “corporate development function,” spanning business development and corporate strategy, the company said.

Pfizer, never one to shy away from a transaction and famous for its willingness to jump into a megamerger, sees plenty of deal activity, which is just what Biogen’s seeking. The company touted Karp’s “strong track record of success leading licensing and M&A transactions,” while CEO Michel Vounatsos—to whom Karp will directly report—praised the “solid experience” that will “serve him well in this exciting position as we aim to further build our pipeline and portfolio.”

Biogen is looking for new revenue streams as competition to its multiple sclerosis portfolio heats up. Last year, Roche piled on the pressure with the approval of blockbuster-to-be Ocrevus, and forthcoming generic versions of Gilenya—a Novartis rival to Biogen’s oral star Tecfidera—will make matters worse next year.

Last April, the company shelled out $300 million upfront and up to $410 million in milestones to gain access to a Bristol-Myers Squibb’s progressive supranuclear palsy and Alzheimer’s candidate, a move R&D head Michael Ehlers called “just the beginning of a set of very rigorous but highly active deals.”

And since then, it’s struck a series of other deals, including buys of Remedy’s phase 3 stroke drug and Karyopharm’s neurology and inflammation candidate, as well as a $1 billion pact on discovery-stage R&D with Ionis. Earlier this year, rumors also listed Biogen as a potential buyer for activist-pressured Acorda, though so far no deal has taken place.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach